Notice of Annual General Meeting in Orexo AB

Regulatory News:

Participation, etc

Shareholders, who wish to participate in the Meeting, must be recorded in the share register maintained by Euroclear Sweden AB on Thursday 15 April 2010, and notify Orexo of their intention to participate not later than 4 pm on Thursday 15 April 2010 in writing to Orexo AB, P.O. Box 303, SE-751 05 Uppsala, Sweden. Such notification can also be made by telephone +46 (0) 18 780 88 00, by telefax +46 (0) 18 780 88 88, or by e-mail beata.augenblick@orexo.com. The notification shall set forth the name, address, telephone number (daytime), personal/corporate identity number, the number of shares held and, when applicable, information about representatives and assistants. As per the day of this notice there are 23,401,252 shares and votes outstanding in the company.

Shareholders whose shares have been registered in the name of a nominee through the trust department of a bank or similar institution must temporarily register their shares in their own names in the share register maintained by Euroclear Sweden AB to be entitled to participate in the Meeting. Shareholders must inform their nominee of such registration well before Thursday 15 April 2010, when such registration must have been executed.

Shareholders represented by proxy shall issue a written and dated power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a certified copy of a registration certificate for the legal entity shall be appended. The power of attorney and the registration certificate may not be older than one year. The power of attorney in original and, when applicable, the registration certificate, should be submitted to the company by post at the address indicated above well before the Meeting. A proxy form is available at the company’s website www.orexo.com and is sent to shareholders who so request.

Proposal regarding chairman of the Meeting, the number of board members and deputy members of the board of directors, fees for the members of the board of directors and the auditor as well as election of chairman and other members of the board of directors (items 2, 13, 14 and 15)

The nomination committee of Orexo AB, which consists of Håkan Åström (chairman of the board of directors), Björn Odlander (HealthCap and chairman of the nomination committee), Ulrica Slåne (Tredje AP-fonden), Marc Philouze (Apax partners) and Antoine Papiernik (Sofinnova Partners), together representing approximately 40 per cent of the votes for all shares in the company, proposes:

Further, the nomination committee proposes that the Meeting resolves to adopt the board member share plan 2010/2017, whereby the board members in the company will receive Board Shares as part of their board fee, as stipulated above. The nomination committee’s proposal regarding the adoption of the board member share plan 2010/2017 is described in more detail in item 16 below.

Allocation of the company’s result (item 11)

The board of directors and the managing director propose that the company’s retained profits are brought forward.

Proposal regarding the adoption of the board member share plan 2010/2017 and the issuance of warrants to subscribe for new shares, and approval of disposal of the warrants issued under the board member share plan 2010/2017 (item 16)

A. Board member share plan 2010/2017

The nomination committee proposes that the Meeting resolves to adopt Orexo’s board member share plan 2010/2017. Board shares with an option to acquire shares in Orexo, may be issued under the board member share plan ("Board Shares”), whereby each Board Share may be exercised to acquire one share in Orexo for payment of an exercise price corresponding to the quota value of the Orexo share.

Board members participating in Orexo’s board member share plan will receive 50 per cent of their board fee and their fee for committee work, if any, in cash and will be allocated a number of Board Shares, which value at the time of allocation shall correspond to 50 per cent of the remuneration of the board fee and fee for committee work, if any. Board members that, due to tax reasons or any other particular reasons, cannot receive shares shall be offered cash settlement. Issued Board Shares shall not be considered as securities and shall not be transferable to a third party.

The number of Board Shares that shall be allocated to the board member shall be based on the volume weighted average share price for the shares during the five business days following announcement of Orexo’s interim report for the first quarter the year when the board member is elected or re-elected. Allocation of Board Shares will, however, be made with a maximum number that is based on the volume weighted average share price, adjusted down with 10 per cent, for the shares during the trading day that is the day of the annual general meeting the year when the board member is elected or re-elected.

The right to acquire new shares by using the Board Shares is contingent on whether the board member remains as a board member during the whole or only part of the mandate. Vesting is granted with 25 per cent the day after publication of the Orexo’s interim report for the first quarter of the year and with 25 per cent after the publication of the interim reports for the second, third and fourth quarter, during the period of mandate the financial year when the board member is elected or re-elected.

The board member’s right to call for exercise occurs as from the second year following the general meeting that resolved on the allocation of the Board Shares. Exercise can be made on one or several occasions. The Board Shares have a duration as from the resolution on allocation until 31 December 2017. Upon expiration of the board mandate, the board member shall call for exercise of his Board Shares on the earliest of 31 December 2017 and the date six months after the announcement of the interim report that immediately follows after the expiration of the board mandate, whereafter all Board Shares will be forfeited.

The Board Shares shall be issued free of charge and the holders that fall under Swedish tax regulations will be taxed, as income, for the difference between the market value of the Orexo share at the time of the exercise and the exercise price of the Board Share. The Orexo group shall be responsible for and shall pay social security charges in relation thereto.

In order to secure that the company can meet its obligations to the holders of Board Shares at the time of exercise of the Board Shares, it is also proposed that the annual general meeting resolves to issue not more than 30,000 warrants with the right to subscribe for new shares to the wholly-owned subsidiary Pharmacall AB. These warrants shall be used to secure that the company can fulfill its obligations to the holders of Board Shares at the time of exercise.

B. Issue of warrants with the right to subscribe for new shares

The nomination committee proposes that the Company shall issue not more than 30,000 warrants with the right to subscribe for new shares, whereby the company’s share capital may increase with not more than SEK 12,000, corresponding to approximately 0.12 per cent of the share capital and votes. The total number of outstanding warrants under the existing incentive programs, including warrants under the proposed board member share plan, corresponds to approximately 5.73 per cent of the share capital and votes in Orexo on a fully diluted basis.

Only the wholly-owned subsidiary Pharmacall AB shall have the right to subscribe for the warrants with the right and obligation to dispose of the warrants in accordance with below. The warrants shall be issued free of charge. Subscription for new shares, in accordance with the terms and conditions for the warrants, can be made from and including the time of the registration of the warrants with the Swedish Companies Registration Office up to and including 31 December 2017. The subscription price for the warrants (i.e. the amount payable upon exercise of the warrants) shall be SEK 0.4.

C. Approval of disposal of the warrants

The nomination committee proposes that the Meeting approves that Pharmacall AB disposes of the warrants to meet the company’s obligations according to the Board Shares issued under the board member share plan.

The reasons for the deviation from the shareholders’ preferential rights are that it is considered important to motivate and keep board members in Orexo and to provide the board members with an economic interest in Orexo equivalent to the shareholders’. As the board member share plan is intended to be an incentive for Orexo’s board members, it is expected to have a positive effect on the future development of the group and thereby be valuable for the shareholders.

Chapter 16 regarding certain directed issues etc. of the Swedish Companies Act applies to the resolution in accordance with the proposal and thus the resolution requires support of shareholders representing not less than nine tenths of the votes cast as well as the shares represented at the Meeting.

The board of directors’ proposal regarding principles and guidelines for remuneration for the management (item 17)

The board of directors proposes that the Meeting resolves to approve the board of directors’ proposal regarding principles and guidelines for remuneration for the management as set forth below. The proposal is in all material respects in line with earlier applied guidelines for remuneration for the management of the company. "Management” refers to the managing director and the other members of the management group, which in addition to the managing director, consists of five persons. The board of directors has appointed a remuneration committee to prepare matters regarding remuneration and other terms of employment of the management.

Orexo shall offer a total remuneration in line with the market conditions to enable the company to recruit and retain competent personnel. The remuneration to the management shall consist of fixed salary, variable remuneration, long-term incentive programs, pension and other customary benefits. The remuneration is based on the commitment and performance of the individual in relation to individual objectives and joint objectives for the company, which have been determined in advance. The individual performance is evaluated continuously.

The fixed salary is in general reviewed on a yearly basis and shall be based on the qualitative performance of the individual. The fixed salary of the managing director and the management shall be in line with the market conditions. The variable remuneration shall take into consideration the level of responsibility and influence of the individual. The size of the variable remuneration is based on the percentage of set goals met by the individual. The variable remuneration shall amount to not more than 40 per cent of the fixed salary for the managing director and the first deputy managing director and not more than 20 per cent of the fixed salary for the other members of the management. The board of directors shall in addition have the possibility, when considered appropriate and in its sole discretion, to allocate variable remuneration to the management.

Orexo has adopted share based long-term incentive programs intended to promote the company’s long-term interest by motivating and rewarding inter alia the management of the company. The long-term incentive programs consist of warrants and employee stock options.

The managing director and the other members of the management are entitled to benefits under defined contribution pension plans. The pension premiums amount to 21 per cent of the managing director’s and the first deputy managing director’s monthly base salary and the pension premiums for the other members of the management amount to approximately 23 per cent of the fixed yearly salary. The employment agreement of the managing director and the first deputy managing director may be terminated with six months notice. The employment agreements of the other members of the management are subject to termination with a notice period of three to twelve months. The managing director and the first deputy managing director are entitled to a severance payment equivalent to twelve times their respective monthly base salary including pension but excluding bonus they had at the expiry of the employment if the company terminates the employment. There are no agreements on severance payment for the management other than as described above.

The board of directors may, in special circumstances and for specific individuals, decide to deviate from the guidelines.

Resolution regarding nomination committee (item 18)

The board of directors proposes that the Meeting resolves that the company shall have a nomination committee consisting of a representative of each of the four largest shareholders, based on the number of votes held, together with the chairman of the board. The names of the members of the nomination committee and the names of the shareholders they represent shall be made public not later than six months before the annual general meeting and be based on shareholding statistics provided by Euroclear Sweden AB per the last banking day in August 2010. Unless the members of the nomination committee agree otherwise, the member representing the largest shareholder, based on the number of votes held, shall be appointed chairman of the nomination committee. In the event a shareholder that has appointed a member is no longer one of the four largest shareholders, based on the number of votes held, the appointed member shall resign and be replaced by a new member in accordance with the above procedure.

The nomination committee shall prepare and submit proposals to the general meeting on: chairman of the meeting, board members, chairman of the board, board fees to each of the board members and the chairman as well as remuneration for committee work, if any, fees to the company’s auditor, and, when applicable, proposal regarding election of new auditor. Further, the nomination committee shall prepare and propose principles for the composition of the nomination committee to the general meeting 2011.

The board of directors’ proposal regarding authorisation for the board of directors to resolve to issue new shares (item 19)

The board of directors proposes that the annual general meeting resolves to authorize the board of directors to resolve to issue new shares, for the time until the end of the next annual general meeting of the shareholders, for the purpose of allowing purchases of other companies, and products and the entering into of collaboration agreements, at one or more occasions and with or without deviation from the shareholders’ preferential right for payment in cash, by set off, or in kind or otherwise with specific terms. Such issues must not result in the share capital or number of shares being increased with more than 10 per cent, neither result in the share capital of the company exceeding the limits set out in the articles of association as adopted from time to time.

________________________

The annual report and the auditor’s report together with all other documents pursuant to Chapter 7 Section 25 of the Companies Act, the complete proposals regarding items 16, 17, 18 and 19 above, as well as the nomination committees’ motivated statement regarding the proposed board members, will be held available at the company’s office at Virdings allé 32 A, in Uppsala and at the company’s website not later than on 7 April 2010, and will be sent to shareholders who so request and who inform the company of their postal address. Documents relating to the proposal under item 16 above will be sent automatically and free of charge to shareholders who notify the company of their participation in the Meeting.

This information was brought to you by Cision http://www.cisionwire.com